Full-Time

Clinical Laboratory Scientist

Confirmed live in the last 24 hours

Veracyte

Veracyte

501-1,000 employees

Develops genomic tests for cancer diagnosis

Compensation Overview

$36 - $46/hr

+ Bonus + Incentives + Restricted Stock Units

Mid, Senior

San Diego, CA, USA

This is an onsite position based in our San Diego, CA office.

Category
Diagnostics & Laboratory Professionals
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Active California Department of Public Health Clinical Laboratory Scientist (CLS) license or Clinical Genetic Molecular Biology Scientist (CGMBS) license (no exceptions)
  • Must have strong analytical and problem-solving skills
  • Must be detail-oriented and comfortable with technology
  • Must have excellent verbal and written communication skills
  • Experience in high complexity clinical laboratory testing, preferably in molecular diagnostics
  • Performance of molecular testing (PCR, Microarray, Sanger/NGS sequencing) a plus
  • Strong computer skills across diverse platforms
  • Excellent interpersonal communication and team player attitude
  • Ability to adapt to change and a rapid work pace
  • Maintains continuing education units required by California Department of Health Services and New York State Department of Health.
Responsibilities
  • Perform molecular genetic testing on clinical specimens
  • Follow the laboratory's standard operating procedures for specimen handling, processing, test analyses, and recording of test results
  • Perform, review and document laboratory quality control procedures in accordance with the Quality Assurance Program
  • Complete assigned laboratory and non-laboratory tasks
  • Prepare reagents required for laboratory testing
  • Engage in training
  • Perform proficiency testing for the clinical tests
  • Assist in research and validation activities
  • Independently identify and troubleshoot basic issues that could potentially adversely affect test performance
  • Document all corrective actions taken when test systems deviate from the laboratory's established performance specifications
  • Follow the laboratory’s standard operating procedures for quality and environmental health and safety and report all concerns of test quality and/or safety to the Lab Supervisor or Safety Officer
  • Ensure all work is performed in accordance with local, state, and federal regulations and participate in all regulatory inspections
  • Work cooperatively in a team environment support fellow laboratory and management staff
  • Perform any other site/lab specific duties as assigned
Desired Qualifications
  • Performance of molecular testing (PCR, Microarray, Sanger/NGS sequencing) a plus

Veracyte develops and sells advanced genomic tests for the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples like nasal swabs or tissue biopsies, providing insights into the presence and progression of cancer. This allows healthcare providers, such as hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte stands out from competitors by focusing on non-invasive testing methods and continuously investing in research to expand their product offerings. Their goal is to improve cancer diagnosis accuracy, leading to better patient outcomes and more efficient healthcare resource use.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption enhances the precision of Veracyte's genomic tests.
  • Liquid biopsy technology expands Veracyte's market reach with non-invasive alternatives.
  • Global precision medicine initiatives drive demand for Veracyte's advanced diagnostic tools.

What critics are saying

  • AI-based tests may show bias due to non-diverse initial development.
  • ClearLab's 2026 launch may face market penetration and regulatory challenges.
  • Continuous R&D reliance may strain finances if new tests lack validation.

What makes Veracyte unique

  • Veracyte specializes in non-invasive genomic tests for early cancer detection.
  • The Decipher Prostate genomic classifier aids in prostate cancer prognosis.
  • Veracyte's nasal swab test improves early lung cancer risk assessment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-2%

2 year growth

-3%
ETF Daily News
Mar 21st, 2025
Proficio Capital Partners LLC Invests $1.18 Million in Veracyte, Inc. (NASDAQ:VCYT)

Proficio Capital Partners LLC invests $1.18 million in Veracyte, Inc. (NASDAQ:VCYT).

Stock Titan
Mar 19th, 2025
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer.

MLO Online
Feb 17th, 2025
New Data at ASCO demonstrates the performance and clinical utility of Veracyte's Decipher Prostate and Decipher Bladder tests

Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.

MarketBeat
Dec 21st, 2024
HighTower Advisors LLC Makes New Investment in Veracyte, Inc. (NASDAQ:VCYT)

HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).

Inside Precision Medicine
Oct 3rd, 2024
Veracyte's RNA Genetic Test Predicts Black Men's Aggressive Prostate Cancer

That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.